Skip to main content

Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on Influenza (ESWI) Influenza Conference on September 17-20, 2023 at the Palacio de Congresos de Valencia in Valencia, Spain.

Date/Time: Sunday, September 17, 2023, from 20:00 – 21:00 CEST / 2:00 – 3:00 PM EDT (Sneak Peak)

Date/Time: Monday, September 18, 2023, from 19:30 – 21:00 CEST / 1:30 – 3:00 PM EDT

Abstract Number: 663

Poster Title: “EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results from a Phase 1 Study in Healthy Subjects and Correlation with In Vitro Antiviral Activity”

Location: Poster Hall Exhibit

Presenter: Kimberly Mills, PharmD

Further information about the ESWI Influenza Conference can be found here.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET®.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  257.89
+0.14 (0.05%)
AAPL  351.91
-0.87 (-0.25%)
AMD  503.41
-0.87 (-0.17%)
BAC  49.44
-0.64 (-1.28%)
GOOG  277.60
-3.66 (-1.30%)
META  618.87
-7.54 (-1.20%)
MSFT  506.24
-11.75 (-2.27%)
NVDA  155.46
-0.68 (-0.44%)
ORCL  115.00
-4.09 (-3.43%)
TSLA  380.11
+0.37 (0.10%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.